Role of endoscopic duodenojejunal bypass liner in obesity management and glycemic control
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The treatment of obesity and its comorbidities ranges from clinical management involving lifestyle changes and medications to bariatric and metabolic surgery. Various endoscopic bariatric and metabolic therapies recently emerged to address an important therapeutic gap by offering a less invasive alternative to surgery that is more effective than conservative therapies. This article comprehensively reviews the technical aspects, mechanism of action, outcomes, and future perspectives of one of the most promising endoscopic bariatric and metabolic therapies, named duodenojejunal bypass liner. The duodenojejunal bypass liner mimics the mechanism of Roux-en-Y gastric bypass by preventing food contact with the duodenum and proximal jejunum, thereby initiating a series of hormonal changes that lead to delayed gastric emptying and malabsorptive effects. These physiological changes result in significant weight loss and improved metabolic control, leading to better glycemic levels, preventing dyslipidemia and non-alcoholic fatty liver disease, and mitigating cardiovascular risk. However, concern exists regarding the safety profile of this device due to the reported high rates of severe adverse events, particularly liver abscesses. Ongoing technical changes aiming to reduce adverse events are being evaluated in clinical trials and may provide more reliable data to support its routine use in clinical practice.
Abstract
The treatment of obesity and its comorbidities ranges from clinical management involving lifestyle changes and medications to bariatric and metabolic surgery. Various endoscopic bariatric and metabolic therapies recently emerged to address an important therapeutic gap by offering a less invasive alternative to surgery that is more effective than conservative therapies. This article comprehensively reviews the technical aspects, mechanism of action, outcomes, and future perspectives of one of the most promising endoscopic bariatric and metabolic therapies, named duodenojejunal bypass liner. The duodenojejunal bypass liner mimics the mechanism of Roux-en-Y gastric bypass by preventing food contact with the duodenum and proximal jejunum, thereby initiating a series of hormonal changes that lead to delayed gastric emptying and malabsorptive effects. These physiological changes result in significant weight loss and improved metabolic control, leading to better glycemic levels, preventing dyslipidemia and non-alcoholic fatty liver disease, and mitigating cardiovascular risk. However, concern exists regarding the safety profile of this device due to the reported high rates of severe adverse events, particularly liver abscesses. Ongoing technical changes aiming to reduce adverse events are being evaluated in clinical trials and may provide more reliable data to support its routine use in clinical practice.
참고문헌 (42)
- "World Obesity Atlas 2023" (2023)[URL]
- Michaelidou M, "Management of diabesity : current concepts", World J Diabetes, 14, pp.396~411 (2023)
- Na HK, "Various novel and emerging technologies in endoscopic bariatric and metabolic treatments", Clin Endosc, 54, pp.25~31 (2021)
- Cambi MP, "Multidisciplinary approach for weight regain-how to manage this challenging condition : an expert review", Obes Surg, 31, pp.1290~1303 (2021)
- Colquitt JL, "Surgery for weight loss in adults", Cochrane Database Syst Rev, 2014, pp.CD003641~ (2014)
- Nguyen NT, "Trends in use of bariatric surgery, 2003-2008", J Am Coll Surg, 213, pp.261~266 (2011)
- Tatarian T, "Evolving procedural options for the treatment of obesity", Curr Probl Surg, 57, pp.100742~ (2020)
- Günthert SJ, "Glycemic control and BMI changes after endoscopic implantation of a duodenojejunal bypass liner compared with laparoscopic Roux-en-Y gastric bypass surgery : a propensity score matching analysis", Surg Endosc, 36, pp.5979~5985 (2022)
- Betzel B, "Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation", Surg Endosc, 34, pp.209~215 (2020)
- Simons M, "Updates in metabolic bariatric endoscopy", Dig Endosc, 36, pp.107~115 (2023)
- Shenoy A, "Advances in endobariatrics: past, present, and future", Gastroenterol Rep (Oxf), 11, pp.goad043~ (2023)
- Dave N, "Endobariatrics : a still underutilized weight loss tool", Curr Treat Options Gastroenterol, 21, pp.172~184 (2023)
- McCarty TR, "The current state of bariatric endoscopy", Dig Endosc, 33, pp.321~334 (2021)
- Campbell JE, "Pharmacology, physiology, and mechanisms of incretin hormone action", Cell Metab, 17, pp.819~837 (2013)
- Chen JH, "Research progress of duodenal-jejunal bypass liner in the treatment of obesity and type 2 diabetes mellitus", Diabetes Metab Syndr Obes, 15, pp.3319~3327 (2022)
- Jirapinyo P, "Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity : a meta-analysis with secondary analysis on weight loss and hormonal changes", Diabetes Care, 41, pp.1106~1115 (2018)
- de Moura EG, "Effects of duodenal-jejunal bypass liner(EndoBarrier®)on gastric emptying in obese and type 2 diabetic patients", Obes Surg, 25, pp.1618~1625 (2015)
- Yvamoto EY, "The effectiveness and safety of the duodenal-jejunal bypass liner(DJBL)for the management of obesity and glycaemic control : a systematic review and meta-analysis of randomized controlled trials", Obes Surg, 33, pp.585~599 (2023)
- Jirapinyo P, "Effect of aspiration therapy on obesity-related comorbidities : systematic review and meta-analysis", Clin Endosc, 53, pp.686~697 (2020)
- Cho JH, "The clinical and metabolic effects of intragastric balloon on morbid obesity and its related comorbidities", Clin Endosc, 54, pp.9~16 (2021)
- Boonchaya-Anant P, "Sustained weight loss after duodenal-jejunal bypass liner treatment in patients with body mass index below, but not above 35 kg", m2 : a retrospective cohort study, 2023, pp.13, e12561~
- van Rijn S, "Effect of the EndoBarrier device : a 4-year follow-up of a multicenter randomized clinical trial", Obes Surg, 29, pp.1117~1121 (2019)
- Ryder RE, "Endoscopic duodenal-jejunal bypass liner treatment for type 2 diabetes and obesity : glycemic and cardiovascular disease risk factor improvements in 1, 022 patients treated worldwide", Diabetes Care, 46, pp.e89~e91 (2023)
- Karlas T, "Endoscopic bariatric treatment with duodenal-jejunal bypass liner improves non-invasive markers of non-alcoholic steatohepatitis", Obes Surg, 32, pp.2495~2503 (2022)
- Roehlen N, "Impact of duodenal-jejunal bypass liner(DJBL)on NAFLD in patients with obesity and type 2 diabetes mellitus", Nutrition, 103-104, pp.111806~ (2022)
- Vilarrasa N, "Nutritional deficiencies and bone metabolism after endobarrier in obese type 2 patients with diabetes", Eur J Clin Nutr, 72, pp.1447~1450 (2018)
- Roehlen N, "Duodenal-jejunal bypass liner(DJBL)improves cardiovascular risk biomarkers and predicted 4-year risk of major CV events in patients with type 2 diabetes and metabolic syndrome", Obes Surg, 30, pp.1200~1210 (2020)
- Betzel B, "Adverse events of the duodenal-jejunal bypass liner : a systematic review", Obes Surg, 28, pp.3669~3677 (2018)
- Cotton PB, "A lexicon for endoscopic adverse events : report of an ASGE workshop", Gastrointest Endosc, 71, pp.446~454 (2010)
- Dindo D, "Classification of surgical complications : a new proposal with evaluation in a cohort of 6336 patients and results of a survey", Ann Surg, 240, pp.205~213 (2004)
- Nass KJ, "Novel classification for adverse events in GI endoscopy : the AGREE classification", Gastrointest Endosc, 95, pp.1078~1085 (2022)
- De Moura EG, "Endoscopic management of anchor erosion adjacent to the pylorus following duodenal-jejunal bypass sleeve", Obes Surg, 29, pp.2003~2004 (2019)
- Laubner K, "Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus : a case control study", Diabetes Obes Metab, 20, pp.1868~1877 (2018)
- ASGE, "ASMBS Task Force on Endoscopic Bariatric Therapy", A pathway to endoscopic bariatric therapies, 2011, pp.7, 672~682
- ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, "ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies", Gastrointest Endosc, 82, pp.425~438 (2015)
- Mauro A, "A comprehensive review on bariatric endoscopy : where we are now and where we are going", Medicina(Kaunas), 59, pp.636~ (2023)
- Singh S, "Primary obesity surgery endoluminal(POSE)for the treatment of obesity : a systematic review and meta-analysis", Surg Endosc, 36, pp.252~266 (2022)
- de Oliveira GH, "Metabolic effects of endoscopic duodenal mucosal resurfacing : a systematic review and meta-analysis", Obes Surg, 31, pp.1304~1312 (2021)
- Kotinda AP, "Efficacy of intragastric balloons for weight loss in overweight and obese adults : a systematic review and meta-analysis of randomized controlled trials", Obes Surg, 30, pp.2743~2753 (2020)
- de Miranda Neto AA, "Efficacy and safety of endoscopic sleeve gastroplasty at mid term in the management of overweight and obese patients : a systematic review and meta-analysis", Obes Surg, 30, pp.1971~1987 (2020)
- Huberty V, "Endoscopic sutured gastroplasty in addition to lifestyle modification : short-term efficacy in a controlled randomised trial", Gut, 70, pp.1479~1485 (2021)
- Ren M, "Small intestine-targeted endoscopic bariatrics : current status and future perspectives", Dig Endosc, 35, pp.684~697 (2023)